Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on May 17, 2018. The report covers a specific corporate event occurring on the same date regarding the company's clinical trial progress.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical milestone and does not contain financial statements.
Material Changes
The material event reported is the completion of the first dose cohort in the Phase 1b/2 clinical trial of PCM-075. PCM-075 is a highly-selective Polo-like Kinase 1 (PLK1) Inhibitor being tested in combination with LDAC for the treatment of Acute Myeloid Leukemia (AML).
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the clinical milestone. The filing does not provide specific financial guidance, future outlook projections, or detailed risk factors beyond the inherent nature of clinical trials. A press release detailing the event is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Review the attached press release (Exhibit 99.1) for specific data on the PCM-075 trial results.
- Confirm the status of the Phase 1b/2 trial for Acute Myeloid Leukemia (AML).
- Check subsequent filings for financial updates, as this 8-K contains no financial data.